Structure

InChI Key MWHXMIASLKXGBU-RNCYCKTQSA-N
Smile CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O
InChI
InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C30H41NO7
Molecular Weight 527.66
AlogP 5.38
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 10.0
Polar Surface Area 49.77
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Muscarinic acetylcholine receptor M2 antagonist ISBN PubMed PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Urinary Incontinence 3 D014549 ClinicalTrials

Related Entries

MCS

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
16.89
Gastrointestinal disorders
15.2
Nervous system disorders
10.55
Renal and urinary disorders
9.13
Injury, poisoning and procedural complications
6.29
Psychiatric disorders
5.69
Respiratory, thoracic and mediastinal disorders
5.18
Musculoskeletal and connective tissue disorders
4.49
Skin and subcutaneous tissue disorders
3.61
Cardiac disorders
3.5
Vascular disorders
3.41
Investigations
2.91
Infections and infestations
2.9
Eye disorders
2.77
Immune system disorders
2.46

Cross References

Resources Reference
ChEMBL CHEMBL1201765
FDA SRS EOS72165S7
PubChem 9849808
SureChEMBL SCHEMBL814971